title: Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease.
abstract: OBJECTIVE
  Free fatty acid inhibition with trimetazidine (TMZ) improves myocardial metabolism and myocardial ischemia in patients with coronary artery disease (CAD). Because of its effect on myocardial glucose utilization TMZ may represent a therapeutic option in diabetic patients with CAD. Aim of the present study was to evaluate whether the metabolic effect of TMZ may improve episodes of myocardial ischemia in diabetic patients with CAD.
  
  
  METHODS
  We assessed the effect of TMZ on 24 h ambulatory ECG monitoring (AEM) in 30 patients (22 males and 8 females, mean (SE) age 67+/-6.5 years) with NIDDM and ischemic cardiomyopathy. Patients were randomized to receive on top of standard therapy either TMZ (20 mg, tds) or placebo (tds) and were evaluated at baseline and after 6 months.
  
  
  RESULTS
  Patients randomized to TMZ or placebo were comparable regarding demographic data, distribution of CAD, and glicated haemoglobin levels. TMZ significantly reduced the number of episodes of transient myocardial ischemia (-24% compared to baseline, p<0.01; -27% compared to placebo, p<0.01), and Total Ischemic Burden (-28% compared to baseline, p<0.01; -29% compared to placebo, p<0.01). TMZ also significantly reduced the number of silent episodes of myocardial ischemia (-42% compared to baseline and -39% compared to placebo, p<0.01) and the time of silent myocardial ischemia/24 h (-37% compared to baseline and -35% compared to placebo, p<0.01). No significant changes in heart rate were detected between baseline, placebo and TMZ evaluations.
  
  
  CONCLUSIONS
  TMZ is effective in reducing silent and symptomatic episodes of transient myocardial ischemia in diabetic patients with CAD on standard anti-anginal therapy.
authors.affiliation: Department of Medical Sciences, Centre for Clinical and Basic Research, IRCCS San Raffaele, Roma, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Marazzi
authors.forename: Mauricio
authors.initials: M
authors.lastname: Wajngarten
authors.forename: Cristiana
authors.initials: C
authors.lastname: Vitale
authors.forename: Roberto
authors.initials: R
authors.lastname: Patrizi
authors.forename: Francesco
authors.initials: F
authors.lastname: Pelliccia
authors.forename: Otavio
authors.initials: O
authors.lastname: Gebara
authors.forename: Humberto
authors.initials: H
authors.lastname: Pierri
authors.forename: Josè Antonio F
authors.initials: JA
authors.lastname: Ramires
authors.forename: Maurizio
authors.initials: M
authors.lastname: Volterrani
authors.forename: Massimo
authors.initials: M
authors.lastname: Fini
authors.forename: Giuseppe M C
authors.initials: GM
authors.lastname: Rosano
mesh_terms: D000368:Aged; D003324:Coronary Artery Disease / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004311:Double-Blind Method; D015716:Electrocardiography, Ambulatory; D005230:Fatty Acids, Nonesterified / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000209:etiology / Q000517:prevention & control*; D010084:Oxidation-Reduction / Q000187:drug effects; D014292:Trimetazidine / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D005230:Fatty Acids, Nonesterified; D014665:Vasodilator Agents; D014292:Trimetazidine